Theme Member
Professor Andrew Zannettino

Contact Details

Phone: 08 8128 4390

Email: Andrew.zannettino@adelaide.edu.au

https://www.researchgate.net/profile/Andrew_Zannet...

https://scholar.google.com.au/citations?user=jMUCM2IAAAAJ&hl=en&oi=ao

Qualifications:

BSc (Hons)

PhD

Biography/Research Focus

Professor Zannettino graduated with his Ph.D. from the University of Adelaide in November 1997 and is the Professor of Experimental Haematology and the Deputy Head of the School of Medical Sciences, Faculty of Health Science, University of Adelaide. He holds a Professorial appointment with the Royal Adelaide Hospital Cancer Centre, Central Adelaide Local Health Network and is faculty member of the Centre for Cancer Biology (SA Pathology) and Centre for Personalised Cancer Medicine (University of Adelaide).

Professor Zannettino heads the Myeloma Research Laboratory (MRL) and co-heads the Regenerative Medicine Program (RMP). The MRL’s efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression and myeloma-associated bone loss. The RMP stems from collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, University of Adelaide) and Prof Paul Simmons (Mesoblast Ltd), which led to the patenting of technologies covering the identification and isolation of Mesenchymal Precursor Cells (MPC), a rare cell population present in many post-natal tissues. The family of 7 patents surrounding this technology underpin the world’s largest cell therapy company, Mesoblast Ltd. Professor Zannettino has served as a consultant to Mesoblast Ltd since 2004. He has also served on the Myeloma Foundation of Australia-Medical and Scientific Advisory Group since its inception and is on the board of management for the Robinson Research Institute, the Bone Health Foundation and the Colgate Australian Clinical Dental Research Centre.

Publications

ORIGINAL RESEARCH ARTICLES

  1. Forristal C.E., Brown A., Helwani F.M., Winkler I.G., Nowlan B., Powell J., Engler G., Diakiw S.M., Zannettino A.C.W., Martin, S.K., Pattabiraman D., DÁndrea R., Lewis I., Levesque J.P. Hypoxia inducible factor (HIF-2a) enhances proliferation of malignant hematopoietic cells and disease progression in the hypoxic malignant bone marrow. Manuscript accepted, Leukemia.
  2. Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leuk Res. 2015;39(3):380-387.
  3. Nguyen T-V, Melville A, Nath S, Story C, Howell S, Sutton R, Zannettino A, Revesz T. Bone Marrow Recovery by Morphometry During Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children. Manuscript accepted, PLOsONE
  4. Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino ACW, Burns CJ, Walkley CR. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Manuscript accepted, Scientific Reports
  5. Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin Cancer Res. 2015 Apr 10. pii: clincanres.3026.2014. [Epub ahead of print]
  6. Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, Zannettino AC, Vandyke K. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Exp Cell Res. 2015.
  7. Cakouros D, Isenmann S, Hemming SE, Menicanin D, Camp E, Zannettino AC, Gronthos S. Novel basic helix loop helix transcription factor Hes4 antagonizes the function of Twist-1 to regulate lineage commitment of bone marrow stromal/ stem cells. Stem Cells Dev. 2015.
  8. Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Lett. 2015;357(1):160-169.
  9. Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin Cancer Res. 2015.
  10. Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2015;94(4):343-354.
  11. Martin SK, Fitter S, Dutta AK, Matthews MP, Walkley CR, Hall MN, Ruegg MA, Gronthos S, Zannettino AC. The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells. 2015;33(4):1359-1365.
  12. Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2014.
  13. Ahmed F, Choudhury NR, Dutta NK, Brito e Abreu S, Zannettino A, Duncan E. Interaction of platelets with poly(vinylidene fluoride-co-hexafluoropropylene) electrospun surfaces. Biomacromolecules. 2014;15(3):744-755.
  14. Hemming S, Cakouros D, Isenmann S, Cooper L, Menicanin D, Zannettino A, Gronthos S. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells. 2014;32(3):802-815.
  15. Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia. 2014;16(7):572-585.
  16. Noll JE, Williams SA, Tong CM, Wang H, Quach JM, Purton LE, Pilkington K, To LB, Evdokiou A, Gronthos S, Zannettino AC. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163-171.
  17. Frith JE, Menzies DJ, Cameron AR, Ghosh P, Whitehead DL, Gronthos S, Zannettino AC, Cooper-White JJ. Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials. 2014;35(4):1150-1162.
  18. Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Res. 2014;34(12):7007-7020.
  19. Zinonos I, Luo KW, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ko CH, Yue GG, Lau CB, Ingman W, Ponomarev V, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. Int J Oncol. 2014;45(2):532-540.
  20. Ahmed F, Dutta NK, Zannettino A, Vandyke K, Choudhury NR. Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules. 2014;15(4):1276-1287.
  21. Richardson JD, Psaltis PJ, Frost L, Paton S, Carbone A, Bertaso AG, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG. Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy. 2014;16(4):460-470.
  22. Ahmed F, Roy Choudhury N, Dutta NK, Zou L, Zannettino A. Fabrication and characterisation of an electrospun tubular 3D scaffold platform of poly(vinylidene fluoride-co-hexafluoropropylene) for small-diameter blood vessel application. J Biomater Sci Polym Ed. 2014;25(18):2023-2041.
  23. Richardson JD, Bertaso AG, Frost L, Psaltis PJ, Carbone A, Koschade B, Wong DT, Nelson AJ, Paton S, Williams K, Azarisman S, Worthley MI, Teo KS, Gronthos S, Zannettino AC, Worthley SG. Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of in vivo assessment of ventricular function in rats. Lab Anim. 2013;47(4):291-300.
  24. Ahmed F, Choudhury NR, Dutta NK, Zannettino A, Knott R. Near superhydrophobic fibrous scaffold for endothelialization: fabrication, characterization and cellular activities. Biomacromolecules. 2013;14(11):3850-3860.
  25. Richardson JD, Bertaso AG, Psaltis PJ, Frost L, Carbone A, Paton S, Nelson AJ, Wong DT, Worthley MI, Gronthos S, Zannettino AC, Worthley SG. Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. J Card Fail. 2013;19(5):342-353.
  26. Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br J Haematol. 2013;161(4):499-507.
  27. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab. 2013;98(1):67-76.
  28. Frith JE, Cameron AR, Menzies DJ, Ghosh P, Whitehead DL, Gronthos S, Zannettino AC, Cooper-White JJ. An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials. 2013;34(37):9430-9440.
  29. Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, Vandyke K, Zannettino AC, Koblar SA, Sims NA, Matsuo K, Gronthos S. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. J Bone Miner Res. 2013;28(4):926-935.
  30. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biol. 2013;11(3):e1001515.
  31. Crotti TN, Dharmapatni AA, Alias E, Zannettino AC, Smith MD, Haynes DR. The immunoreceptor tyrosine-based activation motif (ITAM) -related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther. 2012;14(6):R245.
  32. Macsai CE, Georgiou KR, Foster BK, Zannettino AC, Xian CJ. Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone. 2012;50(5):1081-1091.
  33. Ghosh P, Moore R, Vernon-Roberts B, Goldschlager T, Pascoe D, Zannettino A, Gronthos S, Itescu S. Immunoselected STRO-3+ mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs. J Neurosurg Spine. 2012;16(5):479-488.
  34. Weber B, Emmert MY, Behr L, Schoenauer R, Brokopp C, Drogemuller C, Modregger P, Stampanoni M, Vats D, Rudin M, Burzle W, Farine M, Mazza E, Frauenfelder T, Zannettino AC, Zund G, Kretschmar O, Falk V, Hoerstrup SP. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials. 2012;33(16):4031-4043.
  35. Fitter S, Vandyke K, Gronthos S, Zannettino AC. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol. 2012;48(3):229-240.
  36. Castrechini NM, Murthi P, Qin S, Kusuma GD, Wilton L, Abumaree M, Gronthos S, Zannettino A, Gude NM, Brennecke SP, Kalionis B. Decidua parietalis-derived mesenchymal stromal cells reside in a vascular niche within the choriodecidua. Reprod Sci. 2012;19(12):1302-1314.
  37. Cakouros D, Isenmann S, Cooper L, Zannettino A, Anderson P, Glackin C, Gronthos S. Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A/Arf locus in mesenchymal stem cells. Mol Cell Biol. 2012;32(8):1433-1441.
  38. Nath SV, Nicholson I, Tapp H, Zola H, Zannettino AC, Revesz T. Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Med Hypotheses. 2011;77(3):333-335.
  39. Freeman LM, Lam A, Petcu E, Smith R, Salajegheh A, Diamond P, Zannettino A, Evdokiou A, Luff J, Wong PF, Khalil D, Waterhouse N, Vari F, Rice AM, Catley L, Hart DN, Vuckovic S. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. J Immunol. 2011;187(8):3987-3996.
  40. See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, Govaert KM, Schuster MD, Kurlansky PA, Kelly DJ, Krum H, Itescu S. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med. 2011;15(10):2117-2129.
  41. Arthur A, Zannettino A, Panagopoulos R, Koblar SA, Sims NA, Stylianou C, Matsuo K, Gronthos S. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone. 2011;48(3):533-542.
  42. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Findlay DM, Zannettino AC, Evdokiou A. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res. 2011;26(3):630-643.
  43. Psaltis PJ, Carbone A, Leong DP, Lau DH, Nelson AJ, Kuchel T, Jantzen T, Manavis J, Williams K, Sanders P, Gronthos S, Zannettino AC, Worthley SG. Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. Int J Cardiovasc Imaging. 2011;27(1):25-37.
  44. Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica. 2011;96(2):213-220.
  45. Vandyke K, Fitter S, Zannettino AC. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J. 2011;1(2):e2.
  46. Andersen DC, Kortesidis A, Zannettino AC, Kratchmarova I, Chen L, Jensen ON, Teisner B, Gronthos S, Jensen CH, Kassem M. Development of novel monoclonal antibodies that define differentiation stages of human stromal (mesenchymal) stem cells. Mol Cells. 2011;32(2):133-142.
  47. Goldschlager T, Ghosh P, Zannettino A, Williamson M, Rosenfeld JV, Itescu S, Jenkin G. A comparison of mesenchymal precursor cells and amnion epithelial cells for enhancing cervical interbody fusion in an ovine model. Neurosurgery. 2011;68(4):1025-1034; discussion 1034-1025.
  48. Field JR, McGee M, Stanley R, Ruthenbeck G, Papadimitrakis T, Zannettino A, Gronthos S, Itescu S. The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Vet Comp Orthop Traumatol. 2011;24(2):113-121.
  49. Dharmapatni AA, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM, Zannettino AC, Zheng TS, Findlay DM, Atkins GJ, Haynes DR. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011;13(2):R51.
  50. Psaltis PJ, Carbone A, Nelson AJ, Lau DH, Jantzen T, Manavis J, Williams K, Itescu S, Sanders P, Gronthos S, Zannettino AC, Worthley SG. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv. 2010;3(9):974-983.
  51. Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood. 2010;116(15):2776-2778.
  52. Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res. 2010;25(10):2126-2137.
  53. Menicanin D, Bartold PM, Zannettino AC, Gronthos S. Identification of a common gene expression signature associated with immature clonal mesenchymal cell populations derived from bone marrow and dental tissues. Stem Cells Dev. 2010;19(10):1501-1510.
  54. Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL, Zannettino AC. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica. 2010;95(5):776-784.
  55. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, Worthley SG, Gronthos S, Zannettino AC. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol. 2010;223(2):530-540.
  56. Castrechini NM, Murthi P, Gude NM, Erwich JJ, Gronthos S, Zannettino A, Brennecke SP, Kalionis B. Mesenchymal stem cells in human placental chorionic villi reside in a vascular niche. Placenta. 2010;31(3):203-212.
  57. Goldschlager T, Ghosh P, Zannettino A, Gronthos S, Rosenfeld JV, Itescu S, Jenkin G. Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model. Neurosurg Focus. 2010;28(6):E4.
  58. Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Levesque JP. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375-385.
  59. Zannettino AC, Paton S, Itescu S, Gronthos S. Comparative assessment of the osteoconductive properties of different biomaterials in vivo seeded with human or ovine mesenchymal stem/stromal cells. Tissue Eng Part A. 2010;16(12):3579-3587.
  60. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95(8):3763-3767.
  61. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010;25(8):1759-1770.
  62. Williams SA, Martin SK, Vincent C, Gronthos S, Zheng T, Atkins GJ, Zannettino AC. Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. Br J Haematol. 2010;150(3):373-376.
  63. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010;24(4):765-770.
  64. Ghosh P, Wu J, Shimmon S, Zannettino AC, Gronthos S, Itescu S. Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Res Ther. 2010;12(1):R28.
  65. McCarty RC, Xian CJ, Gronthos S, Zannettino AC, Foster BK. Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. Open Orthop J. 2010;4:204-210.

REVIEW ARTICLES

  1. Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison S, Mollee P, Roberts A, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45(3):335-343.
  2. Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45(1):94-105.
  3. Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, Spencer A, Szer J, Talaulikar D, To B, Zannettino A, Prince HM. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45(4):371-382.
  4. Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, Spencer A, Szer J, Talaulikar D, To B, Zannettino A, Prince HM. Management of Systemic Light Chain (AL) Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2014.
  5. J.E. N, K. V, A.C.W. Z. The role of the “cancer stem cell niche” in cancer initiation and progression. In: Wislet-Gendebien S, ed. Adult Stem Cell Niches: InTech; 2014:291-320.
  6. Goldschlager T, Oehme D, Ghosh P, Zannettino A, Rosenfeld JV, Jenkin G. Current and future applications for stem cell therapies in spine surgery. Curr Stem Cell Res Ther. 2013;8(5):381-393.
  7. Richardson JD, Nelson AJ, Zannettino AC, Gronthos S, Worthley SG, Psaltis PJ. Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. Stem Cell Rev. 2013;9(3):281-302.
  8. Noll JE, Williams SA, Purton LE, Zannettino AC. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J. 2012;2:e91.
  9. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia. 2011;25(10):1533-1542.
  10. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood. 2010;115(4):766-774.
  11. Goldschlager T, Jenkin G, Ghosh P, Zannettino A, Rosenfeld JV. Potential applications for using stem cells in spine surgery. Curr Stem Cell Res Ther. 2010;5(4):345-355.
  12. Psaltis PJ, Zannettino AC, Gronthos S, Worthley SG. Intramyocardial navigation and mapping for stem cell delivery. J Cardiovasc Transl Res. 2010;3(2):135-146.

Awards/Funding

Grant funding in the last 5 years

GRONTHOS S, ARTHUR A, ZANNETTINO A (CIC). Title of Grant: Osteogenic cell differentiation and function are mediated by ephrinB1 reverse signaling during skeletal development and following the onset of osteoporosis. 2015, 2016, 2017. $548,000 NH&MRC

ZANNETTINO A (CIA), MORGAN G, MULLIGHAN C, TO LB. Title of Grant: Understanding clonal evolution in multiple myeloma. 2014, 2015, 2016. $647,111. NH&MRC

S GRONTHOS, A ZANNETTINO (CIB). Understanding the mechanisms of aberrant bone formation in Saethre- Chotzen syndrome patients with Twist-1 mutations. 2013. $65,000. Centre for Stem Cell Research, UoA Collaborative Grant.

S GRONTHOS, A ZANNETTINO (CIB). Twist-1 inhibits MSC osteoblast differentiation during osteoporosis via direct regulation of the Wnt signalling pathway. 2013, 2014, 2015. $466,044. NHMRC.

ZANNETTINO A (CIA), TO LB. Does Modifying the bone marrow stromal microenvironment alter the disease course of multiple myeloma? 2012. $99,171. Cancer Council/SAHMRI.

GRONTHOS S, ZANNETTINO A (CIB). Mesenchymal Stem Cell maintenance and recruitment during skeletal repair are dependent on EphB-ephrinB signalling. 2012, 2013, 2014. $591,010. NH&MRC

ZANNETTINO A (CIA), TO LB. Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients? 2013, 2014, 2015. $528,666. Cancer Australia and Leukaemia Foundation.

ZANNETTINO A (CIA), GRONTHOS S, FITTER S. The Role of Raptor and Rictor Signalling Pathways in Osteogenesis and Mesenchymal Stem Cell Fate Determination. 2012, 2013, 2014. $543,675. NH&MRC

ZANNETTINO A (CIA). Is mTOR a novel target for the treatment of osteoporosis? 2011 $75,000. Centre for Stem Cell Research

ZANNETTINO A (CIA), GRONTHOS S, FITTER S. The Role of Raptor and Rictor Signalling Pathways in Osteogenesis and Mesenchymal Stem Cell Fate Determination. 2012, 2013, 2014. $543,675. NH&MRC

GRONTHOS S, ZANNETTINO (CIB). Twist-1 Mediated Regulation of Multipotential Mesenchymal Stem Cell Self- Renewal and Cell Fate Determination 2010, 2011, 2012. $583,500. NH&MRC.

ZANNETTINO A (CIA), GRONTHOS S, LEVESQUE J-P, PEET D, TO LB. Is Hypoxia Inducible Factor 2 the Trigger of the Angiogenic Switch and a Driver of Disease Progression in Myeloma?. 2010, 2011, 2012. $583,500. NH&MRC.

EVDOKIOU A, FINDLAY D, ZANNETTINO A (CIC). Antitumour efficacy of TRAIL for the treatment of skeletal malignancies. 2009, 2010, 2011. $441,000. NH&MRC.

ZANNETTINO A (CIA). Abl Kinase Inhibition as a Novel Therapy for Myeloma-Associated Bone Loss 2009, 2010, 2011. US$600,000. United States Leukemia & Lymphoma Society - Translational Research Program

Funding in excess of $650,000 also obtained from commercial funding partners.

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.